High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome
Articles > Article · 2006
Authors: Gülay AŞCI, Hüseyin TÖZ, Mehmet ÖZKAHYA, Seckin CAGIRGAN, Soner DUMAN, Meltem SEZİŞ, Ercan OK
JOURNAL OF NEPHROLOGY, Journal Indexed in SCI Expanded, International, 2006, vol 19, pp 322-326
Summary
Background: Hemophagocytic histiocytic syndrome (HHS) generally occurs in immunocompromised patients and often has a rapidly fatal course. HHS may be cured by treatment of the underlying disorder, especially when it is triggered by an infection. If no cause has been found, no therapy is known and outcome is poor. The aim of this study was to investigate the clinical course and response to intravenous immunoglobulin treatment in renal transplant patients diagnosed with HHS.